Needham & Company Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT), Sees RP-A501 as "Major Value Driver"
Tweet Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and $75.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
